Citi raised the firm’s price target on Lexicon (LXRX) to $1.90 from $1.20 and keeps a Buy rating on the shares following the Q2 report. The firm also opened a “90-day upside catalyst watch” on the shares. Citi expects full data from the PROGRESS Phase 2b study in Q3 to drive a re-rating of Lexicon, noting that management is bullish on the company’s opportunity in pain.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LXRX:
- Lexicon Pharmaceuticals Reports Strong Q2 2025 Results
- Lexicon Pharmaceuticals Reports Strong Q2 2025 Earnings
- Lexicon Pharmaceuticals: Strategic R&D Advancements and Strong Financial Performance Justify Buy Rating
- Lexicon reports Q2 EPS 1c, consensus (8c)
- LXRX Upcoming Earnings Report: What to Expect?